Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Kazuya Kudoh"'
Autor:
Sayaka Ikeda, Yutaka Ueda, Asami Yagi, Shinya Matsuzaki, Eiji Kobayashi, Tadashi Kimura, Etsuko Miyagi, Masayuki Sekine, Takayuki Enomoto, Kazuya Kudoh
Publikováno v:
Expert Review of Vaccines, Vol 18, Iss 4, Pp 323-325 (2019)
Externí odkaz:
https://doaj.org/article/a1de1e7f9e6e41e6b2617ad5180e98bd
Autor:
Jin Suminokura, Sayaka Ikeda, Naohisa Kishimoto, Masashi Takano, Kazuya Kudoh, Kazuki Takasaki, Yuji Ito
Publikováno v:
Medicine: Case Reports and Study Protocols. 2:e0032
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e100c0e26fc396650d20676c7ebd96a1
https://doi.org/10.1097/md9.0000000000000032
https://doi.org/10.1097/md9.0000000000000032
Autor:
Tsunekazu Kita, Takayoshi Asakawa, Hideki Iwahashi, Yoshihiro Kikuchi, Morikazu Miyamoto, Kazuya Kudoh, Hiroko Kouta, Masashi Takano, Hiroko Matsuura, Hiroki Ishibashi, Tadashi Aoyama, Tomoyuki Yoshikawa, Souichirou Kakimoto, Sayaka Ikeda
Publikováno v:
Journal of Clinical Oncology. 37:2592-2592
2592 Background: Cancer cachexia occurs in more than half of cancer patients and can be the primary cause of death for at least 20% of all patients. Cancer cachexia also lowers quality of life in cancer survivors due to a severe loss of skeletal musc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a1e0722f7c3cdb2fa888f317b5bd638
https://doi.org/10.1200/jco.2019.37.15_suppl.2592
https://doi.org/10.1200/jco.2019.37.15_suppl.2592
Autor:
Hiroki Ishibashi, Tadashi Aoyama, Hideki Iwahashi, Kazuya Kudoh, Tsunekazu Kita, Morikazu Miyamoto, Jin Suminokura, Tomoyuki Yoshikawa, Yoshihiro Kikuchi, Masashi Takano, Hiroko Kouta, Kazuki Takasaki, Miyuki Horikoshi, Hiroko Matsuura, Takayoshi Asakawa, Souichirou Kakimoto, Sayaka Ikeda
Publikováno v:
Journal of Clinical Oncology. 37:e17124-e17124
e17124 Background: The immunotherapy drug, nivolumab, is now approved for several metastatic cancers, and has resulted in responses previously not seen with these cancers. Molecular targeting agents, such as mammalian target of rapamycin (mTOR) inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d14ef29cc44b44e89087ae4e8eb5fb5
https://doi.org/10.1200/jco.2019.37.15_suppl.e17124
https://doi.org/10.1200/jco.2019.37.15_suppl.e17124
Autor:
Ryoko Kikuchi, Tomoyuki Yoshikawa, Yoshihiro Kikuchi, Miyuki Horikoshi, Masashi Takano, Sayaka Ikeda, Kazuki Takasaki, Hiroko Matsuura, Hiroko Kouta, Kazuya Kudoh
Publikováno v:
Journal of Clinical Oncology. 37:11051-11051
11051 Background: Uterine sarcomas are associated with poor prognosis snce the complete remission is extreme rare. Therefore, treatment with chemotherapy including eribulin or trabectedin, hormone therapy or molecular-targeted therapy including pazop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::612080714b1e0ad2e8ba8caa7a36644e
https://doi.org/10.1200/jco.2019.37.15_suppl.11051
https://doi.org/10.1200/jco.2019.37.15_suppl.11051
Autor:
Kazuya Kudoh, Miyuki Horikoshi, Jin Suminokura, Masashi Takano, Hiroko Kouta, Tomoyuki Yoshikawa, Yoshihiro Kikuchi, Hiroko Matsuura, Morikazu Miyamoto
Publikováno v:
Journal of Clinical Oncology. 37:e17059-e17059
e17059 Background: Eribulin is a candidate for paclitaxel-refractory breast cancers, and Bevacizmab (B) is known to enhance efficacy of anti-cancer agents in ovarian cancers. A combination therapy using weekly administration of B with eribulin and ox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b191516ac1855bda9ab2153d36499d83
https://doi.org/10.1200/jco.2019.37.15_suppl.e17059
https://doi.org/10.1200/jco.2019.37.15_suppl.e17059
Autor:
Kazuya Kudoh, Hiroko Kouta, Tomoko Goto, Morikazu Miyamoto, Tsunekazu Kita, Yoshihiro Kikuchi, Masafumi Kato, Masashi Takano, Akio Watanabe, Ryoko Kikuchi
Publikováno v:
Gynecologic Oncology. 122:233-237
Objectives Currently, pegylated liposomal doxorubicin (PLD) is regarded as one of the standard treatment options in recurrent ovarian cancers (ROC). Bevacizumab has shown significant antitumor activity for ROC in single-agent or in combination with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c205c40387a386d973e8c1f7c7c0ec7
https://doi.org/10.1016/j.ygyno.2011.04.046
https://doi.org/10.1016/j.ygyno.2011.04.046
Autor:
Sohei Yamamoto, Osamu Matsubara, Kenichi Furuya, Masashi Takano, Kosuke Miyai, Seiichi Tamai, Shinsuke Aida, Hideyuki Shimazaki, Kazuya Kudoh
Publikováno v:
International Journal of Gynecological Pathology. 29:321-327
We report a case of massive intra-abdominal undifferentiated carcinoma derived from a tiny well-differentiated endometrioid adenocarcinoma of the ovary. The patient, a 56-year-old woman, who presented with a large intra-abdominal mass, underwent cyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a3f02d1a094591a60583af42de3f337
https://doi.org/10.1097/pgp.0b013e3181c4f35f
https://doi.org/10.1097/pgp.0b013e3181c4f35f
Autor:
Yoshihiro Kikuchi, Masashi Takano, Miyuki Horikoshi, Kenichi Furuya, Tsunekazu Kita, Kazuya Kudoh, Hiroko Kouta, Takayoshi Asakawa, Tomoyuki Yoshikwa
Publikováno v:
Journal of Clinical Oncology. 36:e17544-e17544
e17544Background: Cancer cachexia occurs in approximately 80% of cancer patients, and is the primary cause of death for 22–30% of all cancer patients. Cancer cachexia also diminishes quality of lif...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2a08e628c672f9fc00e041bbfe4d5a5
https://doi.org/10.1200/jco.2018.36.15_suppl.e17544
https://doi.org/10.1200/jco.2018.36.15_suppl.e17544
Publikováno v:
Biochemical and Biophysical Research Communications. 391:1318-1323
The effects of cAMP in cell are predominantly mediated by the cAMP-dependent protein kinase (PKA), which is composed of two genetically distinct subunits, catalytic (C) and regulatory (R), forming a tetrameric holoenzyme R(2)C(2). The only known func
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2605828c070ddbbde0536c85f14eb083
https://doi.org/10.1016/j.bbrc.2009.12.026
https://doi.org/10.1016/j.bbrc.2009.12.026